610 patients in Japan were randomized after total hip arthroplasty (THA) to receive either 30mg/day oral edoxaban, or two injections/day 2000 IU enoxaparin, for 11-14 days. The purpose of the study was to examine the efficacy of edoxaban as a thromboprophylactic drug in comparison to enoxaparin, the current gold standard. The primary outcome was the incidence of venous thromboembolism (VTE), used to assess drug efficacy, while secondary outcomes included incidence of bleeding and adverse events, to assess drug safety. Results showed a significant decrease in the incidence of asymptomatic VTE for patients receiving edoxaban, compared to those receiving enoxaparin. No patient of either group demonstrated symptomatic DVT or PE, nor were there any VTE-related deaths in either group. Safety outcomes were similar, with the exception of incidence of minor bleeding, which was significantly higher in the the edoxaban group when compared to the enoxaparin group.